View ValuationBurcon NutraScience 将来の成長Future 基準チェック /56Burcon NutraScienceは、103.4%と39.6%でそれぞれ年率103.4%で利益と収益が成長すると予測される一方、EPSはgrowで103.6%年率。主要情報103.4%収益成長率103.60%EPS成長率Chemicals 収益成長18.0%収益成長率39.6%将来の株主資本利益率n/aアナリストカバレッジLow最終更新日12 Feb 2026今後の成長に関する最新情報Breakeven Date Change • Jul 02Forecast breakeven pushed back to 2023The analyst covering Burcon NutraScience previously expected the company to break even in 2022. New forecast suggests the company will make a profit of CA$577.0k in 2023. Average annual earnings growth of 75% is required to achieve expected profit on schedule.すべての更新を表示Recent updatesお知らせ • Apr 27Burcon NutraScience Corporation announced that it has received CAD 6.9 million in funding from RE ProMan LLCOn April 27, 2026, Burcon NutraScience Corporation closed the transaction. The company announced that it has issued convertible debentures for gross proceeds of CAD 2,900,000 in final tranche. An insider of the Company subscribed for Convertible Debentures totaling approximately CAD 1,700,000 in principal amount under the final tranche. In total, insiders of the Company subscribed for Convertible Debentures totaling approximately CAD 4,400,000 in principal amount in aggregate under the Private Placement.お知らせ • Jan 28Burcon NutraScience Corporation to Report Q3, 2026 Results on Feb 11, 2026Burcon NutraScience Corporation announced that they will report Q3, 2026 results on Feb 11, 2026お知らせ • Nov 13Burcon NutraScience Corporation announced that it expects to receive CAD 4 million in fundingBurcon NutraScience Corporation announced a non-brokered private placement to issue 4,000 convertible debentures at an issue price of CAD 1,000 per debenture for an aggregate principal amount of up to CAD 4,000,000 on November 12, 2025. Insiders of the Company have committed to participating at a minimum of CAD 2,000,000 in principal amount. The Offering is subject to the approval of the Toronto Stock Exchange ("TSX"). Each Convertible Debenture will consist of CAD 1,000 principal amount, bear interest at a rate of 15% per annum, payable in full upon maturity, and be unsecured. The principal amount outstanding under the Convertible Debentures and all accrued and unpaid interest thereon will be payable in cash 48 months from the date of issuance of the Convertible Debentures. The Convertible Debentures will be convertible at the option of the holder, in whole or in part, into common shares of the Corporation (the "Shares") at a conversion price of CAD 2.27 per Share (the "Conversion Price"). The Convertible Debentures and the Shares issuable upon conversion of the Convertible Debentures will be subject to a four month and one day statutory resale restriction pursuant to applicable Canadian securities laws. The Offering is expected to close on or about November 28, 2025 and is subject to execution of subscription agreements by the placees and to certain conditions including, but not limited to, the receipt of all necessary regulatory approvals, including the approval of the TSX.お知らせ • Nov 06Burcon NutraScience Corporation to Report Q2, 2026 Results on Nov 12, 2025Burcon NutraScience Corporation announced that they will report Q2, 2026 results on Nov 12, 2025お知らせ • Jul 30Burcon NutraScience Corporation to Report Q1, 2026 Results on Aug 13, 2025Burcon NutraScience Corporation announced that they will report Q1, 2026 results on Aug 13, 2025お知らせ • Jul 09Burcon NutraScience Corporation, Annual General Meeting, Sep 17, 2025Burcon NutraScience Corporation, Annual General Meeting, Sep 17, 2025. Location: british columbia, vancouver Canadaお知らせ • Jul 02Burcon NutraScience Corporation Unveils Cafe Latte Plant-Based Protein Beverage ConceptBurcon NutraScience Corporation announced to unveil a Cafe Latte plant-based protein beverage concept at the upcoming Institute of Food Technologists Annual Meeting and Exposition ("IFT FIRST") in Chicago, IL, from July 13-16 in exhibit booth S4066. Cold Cafe Latte beverage containing plant proteins photo. The 2025 IFT FIRST food, beverage, foodservice, nutrition and nutraceuticals tradeshow will be held in Chicago July 13-16 and next-generation plant proteins will be front and center. Plant protein innovator Burcon NutraScience (Booth S4066) will feature its range of 90%+ pure pea, sunflower, canola, hemp and fava plant-based proteins with all featuring neutral flavor and aroma, and smooth mouthfeel. During the show, Burcon will be sampling a tasty cold Cafe Latte beverage containing 10 grams of high-purity pea and sunflower seed plant protein in a standard serving. IFT FIRST attendees will have the opportunity to sample the rich, coffee-inspired beverage made with Burcon's proprietary blend of Peazazz®?C pea protein and Solatein™? sunflower protein. The Cafe Latte contains 10 grams of plant protein in an eight-ounce serving showcasing the clean taste, smooth texture, and superior functionality of Burcon's high-purity protein ingredients-delivering an exceptional sensory. experience. In addition to the Cafe Latte, Burcon will exhibit its full portfolio of innovative plant-based proteins, each offering 90%+ protein purity, neutral flavor, and excellent performance for food, beverage, food service, nutritional, and nutraceutical applications. Featured Burcon protein ingredients on display at IFT FIRST include: Peazazz®? C - 90%+ pea protein. Puratein®? C - 90% + canola protein. Solatein™? - 90%+ sunflower protein and a sunflower protein concentrate. HPI95 - 90%+ hempseed protein. FavaPro™? - 90%+ fava protein.お知らせ • Jun 27Burcon NutraScience Corporation Auditor Raises 'Going Concern' DoubtBurcon NutraScience Corporation filed its Annual on Jun 25, 2025 for the period ending Mar 31, 2025. In this report its auditor, KPMG LLP - Klynveld Peat Marwick Goerdeler, gave an unqualified opinion expressing doubt that the company can continue as a going concern.お知らせ • Jun 17Burcon NutraScience Corporation to Report Fiscal Year 2025 Results on Jun 25, 2025Burcon NutraScience Corporation announced that they will report fiscal year 2025 results on Jun 25, 2025お知らせ • Mar 11Burcon NutraScience Corporation (TSX:BU) completed the acquisition of Protein Production Facility.Burcon NutraScience Corporation (TSX:BU) entered into a binding agreement to acquire Protein Production Facility on January 31, 2025. The closing of the transaction is subject to certain conditions, including satisfactory due diligence and approval by the parties. Burcon NutraScience Corporation (TSX:BU) completed the acquisition of Protein Production Facility on March 10, 2025.お知らせ • Feb 13Burcon NutraScience Corporation has completed a Follow-on Equity Offering in the amount of CAD 9.433821 million.Burcon NutraScience Corporation has completed a Follow-on Equity Offering in the amount of CAD 9.433821 million. Security Name: Common Shares Security Type: Common Stock Securities Offered: 110,986,126 Price\Range: CAD 0.085 Transaction Features: Rights Offeringお知らせ • Jan 09Burcon Nutrascience Corporation Announces Launch of Solatein Sunflower Protein Is Now Available for SamplingBurcon NutraScience Corporation announced the launch of SolateinTM sunflower protein isolate, a groundbreaking high-purity protein ingredient designed to meet the evolving preferences of consumers worldwide. An emerging sector of consumers prioritizing protein intake is creating new opportunities for protein supplement products. According to Goldman Sachs Research, the number of GLP-1 weight management medication users is expected to increase rapidly over the next five years. These users are actively seeking protein to support their nutrition needs2. Burcon anticipates that its expanded portfolio of highly differentiated plant-based protein solutions is well-positioned to meet this significant demand. Burcon's SolateinTM sunflower protein is expected to redefine the standards for high-purity protein ingredients. It boasts a neutral flavor, off-white color and exceptional functionality, providing ease of formulation in a variety of food applications, in particular, those with delicate flavors. With over 90% protein purity, SolateinTM is a non-GMO, hypoallergenic protein that surpasses the performance of protein ingredients on the market today. It is rich in sulfur-containing amino acids, which enhances nutritional profiles and complements existing formulations. Burcon's innovative process upcycles by- products from sunflower seed oil production into a highly pure food ingredient, offering a sustainable protein solution.お知らせ • Nov 22Burcon NutraScience Corporation has filed a Follow-on Equity Offering in the amount of CAD 8.671788 million.Burcon NutraScience Corporation has filed a Follow-on Equity Offering in the amount of CAD 8.671788 million. Security Name: Common Share Security Type: Common Stock Securities Offered: 142,628,096 Price\Range: CAD 0.0608 Transaction Features: Rights Offeringお知らせ • Oct 30Burcon NutraScience Corporation to Report Q2, 2025 Results on Nov 13, 2024Burcon NutraScience Corporation announced that they will report Q2, 2025 results on Nov 13, 2024お知らせ • Oct 09Burcon NutraScience Corporation Launches Puratein® Canola ProteinBurcon NutraScience Corporation announced the launch of its Puratein® canola protein into the rapidly growing, multi-billion-dollar egg replacement market. Burcon's canola protein is well-suited for use in baked goods, offering food manufacturers a sustainable and cost- effective alternative to eggs. Egg prices have surged due to supply challenges, with demand outpacing production in the U.S. Over the past two years, avian influenza outbreaks have significantly disrupted egg supplies. According to the U.S. Bureau of Labor Statistics and USDA data, the price of eggs in August 2024 increased by 57% year-over-year, while powdered whole egg prices rose by 15%. As a result, food manufacturers are actively seeking egg substitutes to mitigate supply shortages and price volatility. Burcon's canola protein isolate, with over 90% protein purity and exceptional functionality, is a suitable egg replacement in bakery applications. In a side-by-side study, Burcon's canola protein has demonstrated the ability to replace up to 100% of powdered and shelled eggs, delivering cost-in-use savings of 20 - 30%. This great-tasting canola protein not only provides superior functionality and price stability but also offers a vegan-friendly option for consumers.お知らせ • Sep 20Burcon NutraScience Corporation Announces Board ChangesBurcon NutraScience Corporation at its annual general and special meeting of shareholders held on September 18, 2024, announced that, Mr. James Pekar was elected as a director of the Company. Mr. Pekar has over 30 years' of experience in the dairy and food industry. Born and raised in Wisconsin, United States, Mr. Pekar received a full athletic scholarship to attend the University of Iowa to play football. His football career spanned from 1978 to 1987, from playing with the Iowa Hawkeyes to the LA Express and San Antonio Gunslingers, two USFL football teams. In 1994, Mr. Pekar started a dairy based enzyme-modified reaction company, named First Choice Ingredients, which specialized in reaction, fermentation and distillation technologies. Started in the basement of his first home, Mr. Pekar grew First Choice from one employee to over 150 employees and three plants (which included 150,000+ square feet of office and manufacturing space) and operated the business successfully for 27 years. Dr. Lorne Tyrrell retired from the board of directors and did not stand for re-election at the Meeting this year.お知らせ • Jul 09Burcon NutraScience Corporation, Annual General Meeting, Sep 18, 2024Burcon NutraScience Corporation, Annual General Meeting, Sep 18, 2024.お知らせ • Jun 14Burcon NutraScience Corporation to Report Fiscal Year 2024 Results on Jun 26, 2024Burcon NutraScience Corporation announced that they will report fiscal year 2024 results on Jun 26, 2024お知らせ • Mar 13Burcon NutraScience Corporation announced that it has received CAD 4.36416 million in fundingBurcon NutraScience Corporation announced it has completed an over-subscribed non-brokered private placement of 20,298,418 units at an issue price of CAD 0.215 per Unit for gross proceeds of CAD 4,364,159.87 on March 12, 2024. The transaction included participation from company directors, management, long-term shareholders, and new investors in support of it's long-term vision. Each unit consists of one common share in the capital of the Company and one-half of one Common Share purchase warrant of the Company. Each Warrant entitles the holder thereof to purchase one Common Share at a price of CAD 0.27 per Warrant Share for a period of 24 months after the closing date of the Offering. All securities issued in connection with the Offering are subject to a statutory hold period in Canada expiring four months and one day from the closing of the private placement. n connection with the Offering, the Company paid eligible finders an aggregate cash finder fee of CAD 5,160, representing a cash commission of 4% of the gross proceeds of subscribers introduced to the Company by such finders.お知らせ • Feb 01Burcon NutraScience Corporation to Report Q3, 2024 Results on Feb 14, 2024Burcon NutraScience Corporation announced that they will report Q3, 2024 results on Feb 14, 2024お知らせ • Nov 02Burcon NutraScience Corporation to Report Q2, 2024 Results on Nov 14, 2023Burcon NutraScience Corporation announced that they will report Q2, 2024 results on Nov 14, 2023お知らせ • Sep 21Burcon NutraScience Corporation Announces Board ChangesBurcon NutraScience Corporation announced that, Mr. John A. Vassallo was elected as a director of the Company. Mr. Vassallo has over 30 years' experience in asset acquisition, development and management across several industries in multiple states. As Founder and CEO of Mos RE, LLC, Mr. Vassallo focuses on real estate development, land entitlements, redevelopment and strategic reuse of underutilized buildings by utilizing multi-source financing packages, including historic tax credits, tax incremental financing and state development programs. Mr. Vassallo headed multiple capital raises for a variety of developments and acquisitions. Mr. Vassallo also has experience in purchasing distressed debt for profitable returns. As Founder and CEO of Global Restaurant Systems, LLC, Mr. Vassallo established a multi-faceted management and consulting company providing inclusive restaurant development and operating services including accounting, human resources, real estate analysis and acquisition, legal, marketing, IT and administrative support to its clients. Mr. Vassallo currently holds approximately 3.8% of Burcon's issued and outstanding common shares. Mr. J. Douglas Gilpin did not stand for re-election at the Meeting this year.お知らせ • Jul 08Burcon NutraScience Corporation, Annual General Meeting, Sep 20, 2023Burcon NutraScience Corporation, Annual General Meeting, Sep 20, 2023.お知らせ • Jun 13Burcon NutraScience Corporation to Report Fiscal Year 2023 Results on Jun 22, 2023Burcon NutraScience Corporation announced that they will report fiscal year 2023 results on Jun 22, 2023お知らせ • May 18Burcon NutraScience Corporation announced that it has received CAD 3.41342 million in fundingOn may 16, 2023, the Company has issued a further 3,884,603 Units at a price of CAD 0.265 per Unit for gross proceeds of CAD 1,029,420 for its third and final tranche. Together with the first and second tranche of the Offering, the Company issued a total of 12,880,829 Units for gross proceeds of CAD 3,413,420. In connection with the Offering, the Company paid eligible finders an aggregate cash finder fee of CAD 9,440.お知らせ • May 11Burcon Announces Sunflower Protein Process Commercially ReadyBurcon NutraScience Corporation announce that it has successfully completed end-to-end validation trials of its novel sunflower protein process using commercial-scale equipment at Burcon's Winnipeg Technical Centre. Burcon has validated that its innovative sunflower protein process is robust and ready for commercial scale-up. Burcon's sunflower protein isolates are greater than 90% pure protein, have a neutral flavor profile and are white in color allowing incorporation into many plant-based foods. Initial feedback on Burcon's novel sunflower protein isolate has been overwhelmingly positive. Process validation is a key milestone towards successful commercialization of Burcon's technologies. As part of company's Burcon 2.0 strategy to get closer to customers and end markets, and to have greater control over the manufacture of Burcon's proteins, the Company is evaluating and pursuing multiple routes to market. Discussions with potential partners to bring this technology to market are progressing well, with interested parties wanting to move forward on this project. Concurrent to partnership discussions, Burcon is exploring additional routes to market with the goal of reducing the time required to achieve commercial production and sales.お知らせ • May 10Burcon NutraScience Corporation announced that it expects to receive CAD 3.376451 million in fundingBurcon NutraScience Corporation announced a non-brokered private placement of 12,741,321 units at an issue price of CAD 0.265 per unit for the gross proceeds of CAD 3,376,450 on May 8, 2023. Each unit consists of one common share and one common share purchase warrant. Each warrant entitles the holder thereof to purchase one common share at a price of CAD 0.35 per warrant share for a period of 36 months after the closing date of the transaction. All securities issued in connection with the transaction are subject to a statutory hold period in Canada expiring four months and one day from the closing of the transaction. The Transaction is expected to close in two tranches, the first on May 8, 2023 and the second tranche on or before May 11, 2023. On the same date the company received 5,784,802 units at a price of CAD 0.265 per unit for aggregate gross proceeds of approximately CAD 1,530,000. Each unit consists of one common share and one common share purchase warrant. Each warrant entitles the holder thereof to purchase one common share at a price of $0.35 per warrant share for a period of 36 months after the closing date of the offering. All securities issued in connection with the offering are subject to a statutory hold period in Canada expiring four months and one day from the closing of the private placement. The second tranche is expected on or before May 11, 2023.お知らせ • Feb 02Burcon NutraScience Corporation to Report Q3, 2023 Results on Feb 14, 2023Burcon NutraScience Corporation announced that they will report Q3, 2023 results on Feb 14, 2023Seeking Alpha • Sep 02Burcon NutraScience falls 23% postmarket on delisting of stock from Nasdaq Capital MarketBurcon NutraScience (NASDAQ:BRCN) stock slid 23.1% postmarket on Friday after the firm said it will delist its shares from Nasdaq Capital Market. BRCN shares will be suspended from trading on the exchange on or about Sept. 12. The company in Apr. received a Nasdaq notice indicating that it was not in compliance with the minimum bid price rule. BRCN's management believes it will not be able to regain compliance by the Sept. 28 deadline and a plan for share consolidation would be of no benefit. The company's stock will continue to be listed on the Toronto Stock Exchange. BRCN is exploring listing its stock on either the OTC Pink Open Market or the OTCQB. The firm said its auditors PricewaterhouseCoopers resigned, effective Sept. 1, and will therefore postpone its annual shareholder meeting, which was to be held on Sept. 14. PwC confirmed there were no "reportable events" or "unresolved issues".Reported Earnings • Aug 16First quarter 2023 earnings released: CA$0.04 loss per share (vs CA$0.029 loss in 1Q 2022)First quarter 2023 results: CA$0.04 loss per share (down from CA$0.029 loss in 1Q 2022). Net loss: CA$4.00m (loss widened 26% from 1Q 2022). Over the next year, revenue is forecast to grow 493%, compared to a 12% growth forecast for the Chemicals industry in the US. Over the last 3 years on average, earnings per share has fallen by 4% per year but the company’s share price has fallen by 11% per year, which means it is performing significantly worse than earnings.Seeking Alpha • Aug 15Burcon NutraScience GAAP EPS of -C$0.04, revenue of C$90.54KBurcon NutraScience press release (NASDAQ:BRCN): Q1 GAAP EPS of -C$0.04. Revenue of C$90.54K (+403.0% Y/Y).Reported Earnings • Jun 28Full year 2022 earnings releasedFull year 2022 results: Net loss: CA$10.3m (loss widened CA$9.64m from FY 2021). Over the next year, revenue is forecast to grow 1,092%, compared to a 14% growth forecast for the industry in the US.Seeking Alpha • May 12Burcon: Partner Bunge's $500 Million To $1 Billion Of Growth Capex Within Alternative Proteins Bodes WellPositive development with Bunge disclosing $500 million-$1 billion out of its $2 billion growth capex pipeline is within the alternative protein. Bunge’s increasing interest/spend in plant-based protein is positive for Burcon. Bunge increased its stake in Merit JV with Burcon in 2H’2021 and its path to an even larger Merit stake leads to several positive catalysts for Burcon shares. Non-dilutive $10 million credit line from Burcon’s largest shareholder, Firewood (wholly-owned by Burcon director) is a strong sign of support & positive indicator for the outlook ahead; new JV/CEO next catalysts. Merit shipping to large/small CPG companies globally and expects supply from Phase 1 of the commercial plant to be spoken for by end of 2022; would equate to C$60million in 2023 revenues. Despite overall market volatility, especially in the plant-based sector, the plant-based protein trend remains firmly in place; Nestle's CEO reiterated “once-in-a-generation” opportunity in Feb '22.Buying Opportunity • Apr 11Now 21% undervalued after recent price dropOver the last 90 days, the stock is down 37%. The fair value is estimated to be US$1.02, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 89% over the last 3 years. Meanwhile, the company became loss making. For the next 3 years, revenue is forecast to grow by 47% per annum. Earnings is also forecast to grow by 61% per annum over the same time period.Reported Earnings • Nov 17Second quarter 2022 earnings released: CA$0.01 loss per share (vs CA$0.044 profit in 2Q 2021)Second quarter 2022 results: Net loss: CA$1.35m (down 131% from profit in 2Q 2021). Over the last 3 years on average, earnings per share has increased by 59% per year but the company’s share price has increased by 93% per year, which means it is tracking significantly ahead of earnings growth.Executive Departure • Sep 17Director Chi Ng has left the companyOn the 16th of September, Chi Ng's tenure as Director ended after 2.2 years in the role. We don't have any record of a personal shareholding under Chi's name. A total of 2 executives have left over the last 12 months. The current median tenure of the management team is 12.00 years.Executive Departure • Sep 17Independent Director David Ju has left the companyOn the 16th of September, David Ju's tenure as Independent Director ended after 3.7 years in the role. We don't have any record of a personal shareholding under David's name. A total of 2 executives have left over the last 12 months. The current median tenure of the management team is 12.00 years.Recent Insider Transactions • Sep 12Director recently sold US$69k worth of stockOn the 8th of September, Chi Ng sold around 30k shares on-market at roughly US$2.30 per share. This was the largest sale by an insider in the last 3 months. Insiders have been net sellers, collectively disposing of US$133k more than they bought in the last 12 months.Seeking Alpha • Sep 03Burcon NutraScience: Achieved Several Key Milestones In 1H 2021, Significant Opportunity AheadBurcon disclosed on the quarterly call multiple partnering discussions are underway and the potential for a new collaboration to be announced in the coming months. Any new venture beyond Merit JV will be a major catalyst. In addition to attracting Nestlé & Bunge, Burcon’s best-in-class plant-protein technology has led to Merit executing NDAs with ~240 companies including several of the largest food & beverage companies globally. Burcon’s Merit JV plant has commenced commercial sales of purest pea-based protein & the world’s first protein from canola. Plant achieving remarkable protein levels near 100% purity. The proprietary platform produces essential trifecta with its high-purity plant-based proteins: superior functionality, taste, and nutrition, in a market that is projected to grow seven-fold to ~$290 billion by 2035. A strong potential beneficiary of rising ESG-driven investment trend via new NASDAQ listing as awareness of this pure-play on plant-based protein megatrend increases.Reported Earnings • Aug 21First quarter 2022 earnings released: CA$0.029 loss per share (vs CA$0.014 loss in 1Q 2021)First quarter 2022 results: Net loss: CA$3.18m (loss widened 127% from 1Q 2021). Over the last 3 years on average, earnings per share has increased by 72% per year but the company’s share price has increased by 96% per year, which means it is tracking significantly ahead of earnings growth.Breakeven Date Change • Jul 02Forecast breakeven pushed back to 2023The analyst covering Burcon NutraScience previously expected the company to break even in 2022. New forecast suggests the company will make a profit of CA$577.0k in 2023. Average annual earnings growth of 75% is required to achieve expected profit on schedule.Reported Earnings • Jul 01Full year 2021 earnings releasedFull year 2021 results: Net loss: CA$617.5k (loss narrowed 87% from FY 2020). Over the last 3 years on average, earnings per share has increased by 64% per year but the company’s share price has increased by 97% per year, which means it is tracking significantly ahead of earnings growth.業績と収益の成長予測OTCPK:BRCN.F - アナリストの将来予測と過去の財務データ ( )CAD Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数3/31/202937N/A12N/A13/31/20282558N/A13/31/202714-22N/A13/31/20263-12-8N/A112/31/20251-13-8-7N/A9/30/20251-11-8-7N/A6/30/20250-10-7-6N/A3/31/20250-8-6-6N/A12/31/20240-8-6-6N/A9/30/20240-8-7-6N/A6/30/20240-7-7-6N/A3/31/20240-7-6-6N/A12/31/20230-7-5-5N/A9/30/20230-21-5-5N/A6/30/20230-23-5-5N/A3/31/20230-25-6-6N/A12/31/20220-28-8-7N/A9/30/20220-13-7-7N/A6/30/20220-11-7-7N/A3/31/20220-10-6-6N/A12/31/20210-9-4-4N/A9/30/20210-8-4-4N/A6/30/20210-2-4-3N/A3/31/20210-1-4-3N/A12/31/202000-4-3N/A9/30/202000-3-2N/A6/30/20200-5-3-2N/A3/31/20200-5-3-3N/A12/31/20190-4-4-4N/A9/30/20190-4N/A-4N/A6/30/20190-5N/A-5N/A3/31/20190-5N/A-4N/A12/31/20180-5N/A-4N/A9/30/20180-5N/A-5N/A6/30/20180-5N/A-5N/A3/31/20180-6N/A-5N/A12/31/20170-6N/A-4N/A9/30/20170-5N/A-4N/A6/30/20170-6N/A-5N/A3/31/20170-6N/A-5N/A12/31/20160-6N/A-5N/A9/30/20160-6N/A-5N/A6/30/20160-6N/A-5N/A3/31/20160-7N/A-5N/A12/31/20150-6N/A-5N/A9/30/20150-7N/A-5N/A6/30/20150-7N/A-5N/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: BRCN.Fは今後 3 年間で収益性が向上すると予測されており、これは 貯蓄率 ( 3.5% ) よりも高い成長率であると考えられます。収益対市場: BRCN.F今後 3 年間で収益性が向上すると予想されており、これは市場平均を上回る成長と考えられます。高成長収益: BRCN.F今後 3 年以内に収益を上げることが予想されます。収益対市場: BRCN.Fの収益 ( 39.6% ) US市場 ( 11.4% ) よりも速いペースで成長すると予測されています。高い収益成長: BRCN.Fの収益 ( 39.6% ) 20%よりも速いペースで成長すると予測されています。一株当たり利益成長率予想将来の株主資本利益率将来のROE: BRCN.Fの 自己資本利益率 が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です成長企業の発掘7D1Y7D1Y7D1YMaterials 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/07 05:24終値2026/05/07 00:00収益2025/12/31年間収益2025/03/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Burcon NutraScience Corporation 1 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。4 アナリスト機関Tania Armstrong-WhitworthCanaccord GenuityJacob BoutCIBC Capital MarketsCorey HammillParadigm Capital, Inc.1 その他のアナリストを表示
Breakeven Date Change • Jul 02Forecast breakeven pushed back to 2023The analyst covering Burcon NutraScience previously expected the company to break even in 2022. New forecast suggests the company will make a profit of CA$577.0k in 2023. Average annual earnings growth of 75% is required to achieve expected profit on schedule.
お知らせ • Apr 27Burcon NutraScience Corporation announced that it has received CAD 6.9 million in funding from RE ProMan LLCOn April 27, 2026, Burcon NutraScience Corporation closed the transaction. The company announced that it has issued convertible debentures for gross proceeds of CAD 2,900,000 in final tranche. An insider of the Company subscribed for Convertible Debentures totaling approximately CAD 1,700,000 in principal amount under the final tranche. In total, insiders of the Company subscribed for Convertible Debentures totaling approximately CAD 4,400,000 in principal amount in aggregate under the Private Placement.
お知らせ • Jan 28Burcon NutraScience Corporation to Report Q3, 2026 Results on Feb 11, 2026Burcon NutraScience Corporation announced that they will report Q3, 2026 results on Feb 11, 2026
お知らせ • Nov 13Burcon NutraScience Corporation announced that it expects to receive CAD 4 million in fundingBurcon NutraScience Corporation announced a non-brokered private placement to issue 4,000 convertible debentures at an issue price of CAD 1,000 per debenture for an aggregate principal amount of up to CAD 4,000,000 on November 12, 2025. Insiders of the Company have committed to participating at a minimum of CAD 2,000,000 in principal amount. The Offering is subject to the approval of the Toronto Stock Exchange ("TSX"). Each Convertible Debenture will consist of CAD 1,000 principal amount, bear interest at a rate of 15% per annum, payable in full upon maturity, and be unsecured. The principal amount outstanding under the Convertible Debentures and all accrued and unpaid interest thereon will be payable in cash 48 months from the date of issuance of the Convertible Debentures. The Convertible Debentures will be convertible at the option of the holder, in whole or in part, into common shares of the Corporation (the "Shares") at a conversion price of CAD 2.27 per Share (the "Conversion Price"). The Convertible Debentures and the Shares issuable upon conversion of the Convertible Debentures will be subject to a four month and one day statutory resale restriction pursuant to applicable Canadian securities laws. The Offering is expected to close on or about November 28, 2025 and is subject to execution of subscription agreements by the placees and to certain conditions including, but not limited to, the receipt of all necessary regulatory approvals, including the approval of the TSX.
お知らせ • Nov 06Burcon NutraScience Corporation to Report Q2, 2026 Results on Nov 12, 2025Burcon NutraScience Corporation announced that they will report Q2, 2026 results on Nov 12, 2025
お知らせ • Jul 30Burcon NutraScience Corporation to Report Q1, 2026 Results on Aug 13, 2025Burcon NutraScience Corporation announced that they will report Q1, 2026 results on Aug 13, 2025
お知らせ • Jul 09Burcon NutraScience Corporation, Annual General Meeting, Sep 17, 2025Burcon NutraScience Corporation, Annual General Meeting, Sep 17, 2025. Location: british columbia, vancouver Canada
お知らせ • Jul 02Burcon NutraScience Corporation Unveils Cafe Latte Plant-Based Protein Beverage ConceptBurcon NutraScience Corporation announced to unveil a Cafe Latte plant-based protein beverage concept at the upcoming Institute of Food Technologists Annual Meeting and Exposition ("IFT FIRST") in Chicago, IL, from July 13-16 in exhibit booth S4066. Cold Cafe Latte beverage containing plant proteins photo. The 2025 IFT FIRST food, beverage, foodservice, nutrition and nutraceuticals tradeshow will be held in Chicago July 13-16 and next-generation plant proteins will be front and center. Plant protein innovator Burcon NutraScience (Booth S4066) will feature its range of 90%+ pure pea, sunflower, canola, hemp and fava plant-based proteins with all featuring neutral flavor and aroma, and smooth mouthfeel. During the show, Burcon will be sampling a tasty cold Cafe Latte beverage containing 10 grams of high-purity pea and sunflower seed plant protein in a standard serving. IFT FIRST attendees will have the opportunity to sample the rich, coffee-inspired beverage made with Burcon's proprietary blend of Peazazz®?C pea protein and Solatein™? sunflower protein. The Cafe Latte contains 10 grams of plant protein in an eight-ounce serving showcasing the clean taste, smooth texture, and superior functionality of Burcon's high-purity protein ingredients-delivering an exceptional sensory. experience. In addition to the Cafe Latte, Burcon will exhibit its full portfolio of innovative plant-based proteins, each offering 90%+ protein purity, neutral flavor, and excellent performance for food, beverage, food service, nutritional, and nutraceutical applications. Featured Burcon protein ingredients on display at IFT FIRST include: Peazazz®? C - 90%+ pea protein. Puratein®? C - 90% + canola protein. Solatein™? - 90%+ sunflower protein and a sunflower protein concentrate. HPI95 - 90%+ hempseed protein. FavaPro™? - 90%+ fava protein.
お知らせ • Jun 27Burcon NutraScience Corporation Auditor Raises 'Going Concern' DoubtBurcon NutraScience Corporation filed its Annual on Jun 25, 2025 for the period ending Mar 31, 2025. In this report its auditor, KPMG LLP - Klynveld Peat Marwick Goerdeler, gave an unqualified opinion expressing doubt that the company can continue as a going concern.
お知らせ • Jun 17Burcon NutraScience Corporation to Report Fiscal Year 2025 Results on Jun 25, 2025Burcon NutraScience Corporation announced that they will report fiscal year 2025 results on Jun 25, 2025
お知らせ • Mar 11Burcon NutraScience Corporation (TSX:BU) completed the acquisition of Protein Production Facility.Burcon NutraScience Corporation (TSX:BU) entered into a binding agreement to acquire Protein Production Facility on January 31, 2025. The closing of the transaction is subject to certain conditions, including satisfactory due diligence and approval by the parties. Burcon NutraScience Corporation (TSX:BU) completed the acquisition of Protein Production Facility on March 10, 2025.
お知らせ • Feb 13Burcon NutraScience Corporation has completed a Follow-on Equity Offering in the amount of CAD 9.433821 million.Burcon NutraScience Corporation has completed a Follow-on Equity Offering in the amount of CAD 9.433821 million. Security Name: Common Shares Security Type: Common Stock Securities Offered: 110,986,126 Price\Range: CAD 0.085 Transaction Features: Rights Offering
お知らせ • Jan 09Burcon Nutrascience Corporation Announces Launch of Solatein Sunflower Protein Is Now Available for SamplingBurcon NutraScience Corporation announced the launch of SolateinTM sunflower protein isolate, a groundbreaking high-purity protein ingredient designed to meet the evolving preferences of consumers worldwide. An emerging sector of consumers prioritizing protein intake is creating new opportunities for protein supplement products. According to Goldman Sachs Research, the number of GLP-1 weight management medication users is expected to increase rapidly over the next five years. These users are actively seeking protein to support their nutrition needs2. Burcon anticipates that its expanded portfolio of highly differentiated plant-based protein solutions is well-positioned to meet this significant demand. Burcon's SolateinTM sunflower protein is expected to redefine the standards for high-purity protein ingredients. It boasts a neutral flavor, off-white color and exceptional functionality, providing ease of formulation in a variety of food applications, in particular, those with delicate flavors. With over 90% protein purity, SolateinTM is a non-GMO, hypoallergenic protein that surpasses the performance of protein ingredients on the market today. It is rich in sulfur-containing amino acids, which enhances nutritional profiles and complements existing formulations. Burcon's innovative process upcycles by- products from sunflower seed oil production into a highly pure food ingredient, offering a sustainable protein solution.
お知らせ • Nov 22Burcon NutraScience Corporation has filed a Follow-on Equity Offering in the amount of CAD 8.671788 million.Burcon NutraScience Corporation has filed a Follow-on Equity Offering in the amount of CAD 8.671788 million. Security Name: Common Share Security Type: Common Stock Securities Offered: 142,628,096 Price\Range: CAD 0.0608 Transaction Features: Rights Offering
お知らせ • Oct 30Burcon NutraScience Corporation to Report Q2, 2025 Results on Nov 13, 2024Burcon NutraScience Corporation announced that they will report Q2, 2025 results on Nov 13, 2024
お知らせ • Oct 09Burcon NutraScience Corporation Launches Puratein® Canola ProteinBurcon NutraScience Corporation announced the launch of its Puratein® canola protein into the rapidly growing, multi-billion-dollar egg replacement market. Burcon's canola protein is well-suited for use in baked goods, offering food manufacturers a sustainable and cost- effective alternative to eggs. Egg prices have surged due to supply challenges, with demand outpacing production in the U.S. Over the past two years, avian influenza outbreaks have significantly disrupted egg supplies. According to the U.S. Bureau of Labor Statistics and USDA data, the price of eggs in August 2024 increased by 57% year-over-year, while powdered whole egg prices rose by 15%. As a result, food manufacturers are actively seeking egg substitutes to mitigate supply shortages and price volatility. Burcon's canola protein isolate, with over 90% protein purity and exceptional functionality, is a suitable egg replacement in bakery applications. In a side-by-side study, Burcon's canola protein has demonstrated the ability to replace up to 100% of powdered and shelled eggs, delivering cost-in-use savings of 20 - 30%. This great-tasting canola protein not only provides superior functionality and price stability but also offers a vegan-friendly option for consumers.
お知らせ • Sep 20Burcon NutraScience Corporation Announces Board ChangesBurcon NutraScience Corporation at its annual general and special meeting of shareholders held on September 18, 2024, announced that, Mr. James Pekar was elected as a director of the Company. Mr. Pekar has over 30 years' of experience in the dairy and food industry. Born and raised in Wisconsin, United States, Mr. Pekar received a full athletic scholarship to attend the University of Iowa to play football. His football career spanned from 1978 to 1987, from playing with the Iowa Hawkeyes to the LA Express and San Antonio Gunslingers, two USFL football teams. In 1994, Mr. Pekar started a dairy based enzyme-modified reaction company, named First Choice Ingredients, which specialized in reaction, fermentation and distillation technologies. Started in the basement of his first home, Mr. Pekar grew First Choice from one employee to over 150 employees and three plants (which included 150,000+ square feet of office and manufacturing space) and operated the business successfully for 27 years. Dr. Lorne Tyrrell retired from the board of directors and did not stand for re-election at the Meeting this year.
お知らせ • Jul 09Burcon NutraScience Corporation, Annual General Meeting, Sep 18, 2024Burcon NutraScience Corporation, Annual General Meeting, Sep 18, 2024.
お知らせ • Jun 14Burcon NutraScience Corporation to Report Fiscal Year 2024 Results on Jun 26, 2024Burcon NutraScience Corporation announced that they will report fiscal year 2024 results on Jun 26, 2024
お知らせ • Mar 13Burcon NutraScience Corporation announced that it has received CAD 4.36416 million in fundingBurcon NutraScience Corporation announced it has completed an over-subscribed non-brokered private placement of 20,298,418 units at an issue price of CAD 0.215 per Unit for gross proceeds of CAD 4,364,159.87 on March 12, 2024. The transaction included participation from company directors, management, long-term shareholders, and new investors in support of it's long-term vision. Each unit consists of one common share in the capital of the Company and one-half of one Common Share purchase warrant of the Company. Each Warrant entitles the holder thereof to purchase one Common Share at a price of CAD 0.27 per Warrant Share for a period of 24 months after the closing date of the Offering. All securities issued in connection with the Offering are subject to a statutory hold period in Canada expiring four months and one day from the closing of the private placement. n connection with the Offering, the Company paid eligible finders an aggregate cash finder fee of CAD 5,160, representing a cash commission of 4% of the gross proceeds of subscribers introduced to the Company by such finders.
お知らせ • Feb 01Burcon NutraScience Corporation to Report Q3, 2024 Results on Feb 14, 2024Burcon NutraScience Corporation announced that they will report Q3, 2024 results on Feb 14, 2024
お知らせ • Nov 02Burcon NutraScience Corporation to Report Q2, 2024 Results on Nov 14, 2023Burcon NutraScience Corporation announced that they will report Q2, 2024 results on Nov 14, 2023
お知らせ • Sep 21Burcon NutraScience Corporation Announces Board ChangesBurcon NutraScience Corporation announced that, Mr. John A. Vassallo was elected as a director of the Company. Mr. Vassallo has over 30 years' experience in asset acquisition, development and management across several industries in multiple states. As Founder and CEO of Mos RE, LLC, Mr. Vassallo focuses on real estate development, land entitlements, redevelopment and strategic reuse of underutilized buildings by utilizing multi-source financing packages, including historic tax credits, tax incremental financing and state development programs. Mr. Vassallo headed multiple capital raises for a variety of developments and acquisitions. Mr. Vassallo also has experience in purchasing distressed debt for profitable returns. As Founder and CEO of Global Restaurant Systems, LLC, Mr. Vassallo established a multi-faceted management and consulting company providing inclusive restaurant development and operating services including accounting, human resources, real estate analysis and acquisition, legal, marketing, IT and administrative support to its clients. Mr. Vassallo currently holds approximately 3.8% of Burcon's issued and outstanding common shares. Mr. J. Douglas Gilpin did not stand for re-election at the Meeting this year.
お知らせ • Jul 08Burcon NutraScience Corporation, Annual General Meeting, Sep 20, 2023Burcon NutraScience Corporation, Annual General Meeting, Sep 20, 2023.
お知らせ • Jun 13Burcon NutraScience Corporation to Report Fiscal Year 2023 Results on Jun 22, 2023Burcon NutraScience Corporation announced that they will report fiscal year 2023 results on Jun 22, 2023
お知らせ • May 18Burcon NutraScience Corporation announced that it has received CAD 3.41342 million in fundingOn may 16, 2023, the Company has issued a further 3,884,603 Units at a price of CAD 0.265 per Unit for gross proceeds of CAD 1,029,420 for its third and final tranche. Together with the first and second tranche of the Offering, the Company issued a total of 12,880,829 Units for gross proceeds of CAD 3,413,420. In connection with the Offering, the Company paid eligible finders an aggregate cash finder fee of CAD 9,440.
お知らせ • May 11Burcon Announces Sunflower Protein Process Commercially ReadyBurcon NutraScience Corporation announce that it has successfully completed end-to-end validation trials of its novel sunflower protein process using commercial-scale equipment at Burcon's Winnipeg Technical Centre. Burcon has validated that its innovative sunflower protein process is robust and ready for commercial scale-up. Burcon's sunflower protein isolates are greater than 90% pure protein, have a neutral flavor profile and are white in color allowing incorporation into many plant-based foods. Initial feedback on Burcon's novel sunflower protein isolate has been overwhelmingly positive. Process validation is a key milestone towards successful commercialization of Burcon's technologies. As part of company's Burcon 2.0 strategy to get closer to customers and end markets, and to have greater control over the manufacture of Burcon's proteins, the Company is evaluating and pursuing multiple routes to market. Discussions with potential partners to bring this technology to market are progressing well, with interested parties wanting to move forward on this project. Concurrent to partnership discussions, Burcon is exploring additional routes to market with the goal of reducing the time required to achieve commercial production and sales.
お知らせ • May 10Burcon NutraScience Corporation announced that it expects to receive CAD 3.376451 million in fundingBurcon NutraScience Corporation announced a non-brokered private placement of 12,741,321 units at an issue price of CAD 0.265 per unit for the gross proceeds of CAD 3,376,450 on May 8, 2023. Each unit consists of one common share and one common share purchase warrant. Each warrant entitles the holder thereof to purchase one common share at a price of CAD 0.35 per warrant share for a period of 36 months after the closing date of the transaction. All securities issued in connection with the transaction are subject to a statutory hold period in Canada expiring four months and one day from the closing of the transaction. The Transaction is expected to close in two tranches, the first on May 8, 2023 and the second tranche on or before May 11, 2023. On the same date the company received 5,784,802 units at a price of CAD 0.265 per unit for aggregate gross proceeds of approximately CAD 1,530,000. Each unit consists of one common share and one common share purchase warrant. Each warrant entitles the holder thereof to purchase one common share at a price of $0.35 per warrant share for a period of 36 months after the closing date of the offering. All securities issued in connection with the offering are subject to a statutory hold period in Canada expiring four months and one day from the closing of the private placement. The second tranche is expected on or before May 11, 2023.
お知らせ • Feb 02Burcon NutraScience Corporation to Report Q3, 2023 Results on Feb 14, 2023Burcon NutraScience Corporation announced that they will report Q3, 2023 results on Feb 14, 2023
Seeking Alpha • Sep 02Burcon NutraScience falls 23% postmarket on delisting of stock from Nasdaq Capital MarketBurcon NutraScience (NASDAQ:BRCN) stock slid 23.1% postmarket on Friday after the firm said it will delist its shares from Nasdaq Capital Market. BRCN shares will be suspended from trading on the exchange on or about Sept. 12. The company in Apr. received a Nasdaq notice indicating that it was not in compliance with the minimum bid price rule. BRCN's management believes it will not be able to regain compliance by the Sept. 28 deadline and a plan for share consolidation would be of no benefit. The company's stock will continue to be listed on the Toronto Stock Exchange. BRCN is exploring listing its stock on either the OTC Pink Open Market or the OTCQB. The firm said its auditors PricewaterhouseCoopers resigned, effective Sept. 1, and will therefore postpone its annual shareholder meeting, which was to be held on Sept. 14. PwC confirmed there were no "reportable events" or "unresolved issues".
Reported Earnings • Aug 16First quarter 2023 earnings released: CA$0.04 loss per share (vs CA$0.029 loss in 1Q 2022)First quarter 2023 results: CA$0.04 loss per share (down from CA$0.029 loss in 1Q 2022). Net loss: CA$4.00m (loss widened 26% from 1Q 2022). Over the next year, revenue is forecast to grow 493%, compared to a 12% growth forecast for the Chemicals industry in the US. Over the last 3 years on average, earnings per share has fallen by 4% per year but the company’s share price has fallen by 11% per year, which means it is performing significantly worse than earnings.
Seeking Alpha • Aug 15Burcon NutraScience GAAP EPS of -C$0.04, revenue of C$90.54KBurcon NutraScience press release (NASDAQ:BRCN): Q1 GAAP EPS of -C$0.04. Revenue of C$90.54K (+403.0% Y/Y).
Reported Earnings • Jun 28Full year 2022 earnings releasedFull year 2022 results: Net loss: CA$10.3m (loss widened CA$9.64m from FY 2021). Over the next year, revenue is forecast to grow 1,092%, compared to a 14% growth forecast for the industry in the US.
Seeking Alpha • May 12Burcon: Partner Bunge's $500 Million To $1 Billion Of Growth Capex Within Alternative Proteins Bodes WellPositive development with Bunge disclosing $500 million-$1 billion out of its $2 billion growth capex pipeline is within the alternative protein. Bunge’s increasing interest/spend in plant-based protein is positive for Burcon. Bunge increased its stake in Merit JV with Burcon in 2H’2021 and its path to an even larger Merit stake leads to several positive catalysts for Burcon shares. Non-dilutive $10 million credit line from Burcon’s largest shareholder, Firewood (wholly-owned by Burcon director) is a strong sign of support & positive indicator for the outlook ahead; new JV/CEO next catalysts. Merit shipping to large/small CPG companies globally and expects supply from Phase 1 of the commercial plant to be spoken for by end of 2022; would equate to C$60million in 2023 revenues. Despite overall market volatility, especially in the plant-based sector, the plant-based protein trend remains firmly in place; Nestle's CEO reiterated “once-in-a-generation” opportunity in Feb '22.
Buying Opportunity • Apr 11Now 21% undervalued after recent price dropOver the last 90 days, the stock is down 37%. The fair value is estimated to be US$1.02, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 89% over the last 3 years. Meanwhile, the company became loss making. For the next 3 years, revenue is forecast to grow by 47% per annum. Earnings is also forecast to grow by 61% per annum over the same time period.
Reported Earnings • Nov 17Second quarter 2022 earnings released: CA$0.01 loss per share (vs CA$0.044 profit in 2Q 2021)Second quarter 2022 results: Net loss: CA$1.35m (down 131% from profit in 2Q 2021). Over the last 3 years on average, earnings per share has increased by 59% per year but the company’s share price has increased by 93% per year, which means it is tracking significantly ahead of earnings growth.
Executive Departure • Sep 17Director Chi Ng has left the companyOn the 16th of September, Chi Ng's tenure as Director ended after 2.2 years in the role. We don't have any record of a personal shareholding under Chi's name. A total of 2 executives have left over the last 12 months. The current median tenure of the management team is 12.00 years.
Executive Departure • Sep 17Independent Director David Ju has left the companyOn the 16th of September, David Ju's tenure as Independent Director ended after 3.7 years in the role. We don't have any record of a personal shareholding under David's name. A total of 2 executives have left over the last 12 months. The current median tenure of the management team is 12.00 years.
Recent Insider Transactions • Sep 12Director recently sold US$69k worth of stockOn the 8th of September, Chi Ng sold around 30k shares on-market at roughly US$2.30 per share. This was the largest sale by an insider in the last 3 months. Insiders have been net sellers, collectively disposing of US$133k more than they bought in the last 12 months.
Seeking Alpha • Sep 03Burcon NutraScience: Achieved Several Key Milestones In 1H 2021, Significant Opportunity AheadBurcon disclosed on the quarterly call multiple partnering discussions are underway and the potential for a new collaboration to be announced in the coming months. Any new venture beyond Merit JV will be a major catalyst. In addition to attracting Nestlé & Bunge, Burcon’s best-in-class plant-protein technology has led to Merit executing NDAs with ~240 companies including several of the largest food & beverage companies globally. Burcon’s Merit JV plant has commenced commercial sales of purest pea-based protein & the world’s first protein from canola. Plant achieving remarkable protein levels near 100% purity. The proprietary platform produces essential trifecta with its high-purity plant-based proteins: superior functionality, taste, and nutrition, in a market that is projected to grow seven-fold to ~$290 billion by 2035. A strong potential beneficiary of rising ESG-driven investment trend via new NASDAQ listing as awareness of this pure-play on plant-based protein megatrend increases.
Reported Earnings • Aug 21First quarter 2022 earnings released: CA$0.029 loss per share (vs CA$0.014 loss in 1Q 2021)First quarter 2022 results: Net loss: CA$3.18m (loss widened 127% from 1Q 2021). Over the last 3 years on average, earnings per share has increased by 72% per year but the company’s share price has increased by 96% per year, which means it is tracking significantly ahead of earnings growth.
Breakeven Date Change • Jul 02Forecast breakeven pushed back to 2023The analyst covering Burcon NutraScience previously expected the company to break even in 2022. New forecast suggests the company will make a profit of CA$577.0k in 2023. Average annual earnings growth of 75% is required to achieve expected profit on schedule.
Reported Earnings • Jul 01Full year 2021 earnings releasedFull year 2021 results: Net loss: CA$617.5k (loss narrowed 87% from FY 2020). Over the last 3 years on average, earnings per share has increased by 64% per year but the company’s share price has increased by 97% per year, which means it is tracking significantly ahead of earnings growth.